Drug Profile
Research programme: ROR inhibitors - Kancera
Alternative Names: KAN-0441571Latest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Kancera
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Receptor tyrosine kinase-like orphan receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diffuse large B cell lymphoma; Lymphoma; Solid tumours
Most Recent Events
- 06 Mar 2023 Preclinical development in Lymphoma in Sweden
- 06 Mar 2023 Preclinical development in Solid-tumours in Sweden
- 28 Sep 2020 No recent reports of development identified for preclinical development in Lymphoma in Sweden (PO)